{"id":"NCT02666430","sponsor":"Mylan Inc.","briefTitle":"Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients","officialTitle":"An Open-label, Randomized, Multi-center, Parallel-Group Clinical Trial Comparing the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients: An Extension Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12","primaryCompletion":"2017-03","completion":"2017-07","firstPosted":"2016-01-28","resultsPosted":"2020-09-14","lastUpdate":"2022-03-03"},"enrollment":127,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 1 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Mylan's insulin glargine","otherNames":[]},{"type":"DRUG","name":"Lantus®","otherNames":[]}],"arms":[{"label":"Mylan's insulin glargine","type":"EXPERIMENTAL"},{"label":"Lantus®","type":"ACTIVE_COMPARATOR"}],"summary":"The aim of this extension study is to assess the safety and efficacy of Mylan's insulin glargine and Lantus® in T1DM patients.","primaryOutcome":{"measure":"Change in Hemoglobin A1c (HbA1c) From Baseline","timeFrame":"Baseline to 36 weeks","effectByArm":[{"arm":"Mylan's Insulin Glargine","deltaMin":-0.05,"sd":0.032},{"arm":"Lantus®","deltaMin":-0.06,"sd":0.034}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":81,"countries":["United States","Canada","Czechia","Estonia","Germany","Hungary","Latvia","Slovakia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":64},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Diabetic retinopathy","Influenza","Muscle strain"]}}